Doug McLaughlin

Doug McLaughlin has had a varied career in the life sciences industry. In 2005, they began as a Laboratory Assistant at the Institute of Bioenergetics. In 2006, they became a Marketing Associate at Vision BioSystems. In 2007, they joined Bristol-Myers Squibb as a Temporary Associate, and then moved up to Research Associate I, Research Associate II, Senior Research Associate, and Principal Research Associate between 2008 and 2013. In 2013, they joined Novartis Institutes for BioMedical Research (NIBR) as a Scientist I and then Scientist II from 2015 to 2017. In 2017, they became the Senior Scientist - Head of Protein Sciences at Rubius Therapeutics, and in 2020 they became the Senior Scientist II at MOMA Therapeutics, leading Chemical Genomics (ChemG) efforts.

Doug McLaughlin attended UMass Boston, where they studied Biology. In 2008, they enrolled in the Biotechnology Training Program at Penn State University, focusing on Separation and Purification Strategies for Biotechnology Products.